News

Under the terms of the agreement, Sol-Gel Technologies will receive $24.7 million, comprised of an initial non-refundable payment as well as additional payments upon the successful completion of

The primary efficacy endpoint of the study is reduction of hemolysis from baseline. The study will also measure the effect of Soliris on other clinical manifestations of paroxysmal

The company enrolled 551 obese patients at multiple clinical sites in the US for a six-month, randomized, placebo-controlled dose ranging study. The study is designed to evaluate three

As previously announced, the product patent for GHRH analogues including tesamorelin, granted on January 19, 1999, expires in 2015. The new patent covering the methods of treatment provides

Mr. Nelson has served on Digirad’s board of directors since March 2004. He is currently president and CEO of Uptake Medical. Mr. Nelson said: “Based on my experience

SkinMedica said that the new Desonate (desonide) TwinPack contains two 60gm tubes of Desonate gel for greater coverage of affected areas during the cold-weather season when atopic dermatitis

The company will use the grant proceeds to conduct research that will allow for rapid labeling and purification of specific lineage restricted cells (LRCs) in cultures of differentiating

However, in tandem with this move, the company has also secured access to an incubator space facility in New Brunswick, New Jersey where intramural laboratory-based research will be

The patent covers the composition of matter for humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific antibodies that bind to CD74, the